
<!DOCTYPE html>
<!--[if lt IE 8]>      <html class="no-js nav theme-blue lt-ie10 lt-ie9 lt-ie8  " lang="en-us"> <![endif]-->
<!--[if IE 8]>         <html class="no-js nav theme-blue lt-ie10 lt-ie9  " lang="en-us"> <![endif]-->
<!--[if IE 9]>         <html class="no-js nav theme-blue lt-ie10  " lang="en-us"> <![endif]-->
<!--[if !IE]><!-->     <html class="no-js nav theme-blue  " lang="en-us" > <!--<![endif]-->	
    <head>
        <meta charset="utf-8" />
                		<title>Gonococcal Infections - 2015 STD Treatment Guidelines</title>
        		
        <meta name="description" content="Gonococcal Infections - 2015 STD Treatment Guidelines from CDC" />        <meta name="keywords" content="2015, treatment guidelines, treatment, STD, sexually transmitted diseases, gonorrhea, STI, CDC" />		<meta name="viewport" content="width=device-width, initial-scale=1" />
		        <link rel="apple-touch-icon-precomposed" sizes="144x144" href="../../TemplatePackage/3.0/images/cdc-touch-icon-144x144.png" />
        <link rel="apple-touch-icon-precomposed" sizes="114x114" href="../../TemplatePackage/3.0/images/cdc-touch-icon-114x114.png" />
        <link rel="apple-touch-icon-precomposed" sizes="72x72" href="../../TemplatePackage/3.0/images/cdc-touch-icon-72x72.png" />
        <link rel="apple-touch-icon-precomposed" href="../../TemplatePackage/3.0/images/cdc-touch-icon-57x57.png" />
        <link rel="shortcut icon" href="../../TemplatePackage/3.0/images/favicon.ico" />	
		
		<meta name="robots" content="index,follow" />
		<meta property="cdc:template_version" content="3.0" />
		<meta property="cdc:content-id" content="709559"/>
		<meta property="cdc:revision-id" content="3"/>
				<link rel="canonical" href="http://www.cdc.gov/std/tg2015/gonorrhea.htm"/>
				<!-- Internal Release Version # 3.7.2 -->
                			<link rel="stylesheet" href="../../TemplatePackage/3.0/css/lib/bootstrap24.css" />
	<link rel="stylesheet" href="../../TemplatePackage/3.0/css/app.css@3.2.1.7.css" />
	<!--[if gt IE 9]><!--><!--<![endif]-->
	<!--[if IE 7]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/lib/font-awesome-ie7.css" />
	<![endif]-->
	<!--[if lt IE 9]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/ie.css" />
	<![endif]-->
	<link rel="stylesheet" media="print" href="../../TemplatePackage/3.0/css/print.css@3.2.1.7.css" />
	<script src="../../TemplatePackage/3.0/js/libs/modernizr-latest.js"></script>
	<script>
		if(!Date.now){Date.now=function now(){return new Date().getTime()}}
		var page_timing = page_timing || {};
		page_timing.page_start = Date.now();
		function $$(e){if(window.$){e()}else{setTimeout(function(){$$(e)},50)}}
		// (function(){function e(e,t){var n=e.length;while(n--){if(e[n].indexOf(t)>-1){return e[n]}}return false}var t=e(document.getElementsByTagName("html")[0].className.split(" "),"theme-");if(t){var n=document.createElement("link");n.rel="stylesheet";n.type="text/css";n.media="screen";n.href="/TemplatePackage/3.0/css/themes/"+t+".css";document.getElementsByTagName("head")[0].appendChild(n)}})();

		var settings = {}, addthis = null;
	</script>

	<meta name="application-name" content="CDC.gov"/>
	<meta property="cdc:template_version" content="3.2.1.7" />
	<meta name="msapplication-TileColor" content="#0061aa" />
	<meta name="msapplication-square70x70logo" content="/TemplatePackage/3.0/images/Win8_tile_70x70.png" />
	<meta name="msapplication-square150x150logo" content="/TemplatePackage/3.0/images/Win8_tile_150x150.png" />
	<meta name="msapplication-wide310x150logo" content="/TemplatePackage/3.0/images/Win8_tile_310x150.png" />
	<meta name="msapplication-square310x310logo" content="/TemplatePackage/3.0/images/Win8_tile_310x310.png" />
	<meta name="viewport" content="width=device-width,initial-scale=1,shrink-to-fit=no">		        



                		    </head>
    <body>
				



				<div id="skipmenu">
	<a href="gonorrhea.htm#searchTarget" class="skippy">Skip directly to search</a>
	<a href="gonorrhea.htm#azTab" class="skippy">Skip directly to A to Z list</a>
	<a href="gonorrhea.htm#nav-container" class="skippy">Skip directly to navigation</a>
	<a href="gonorrhea.htm#share-bar" class="skippy">Skip directly to page options</a>
	<a href="gonorrhea.htm#contentArea" class="skippy">Skip directly to site content</a>
</div>		    	<div id="wrapper">
    		
<!-- references to this removed intentionally -->
    		<header id="header">
    			<div class="container">
                    <div class="row">
                    	<div id="logo" class="span14">
                    		<!--iPad touch response and 508 voice reader issue currently under investigation -->
<a href="../../index.html" title="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People">
	<img src="../../TemplatePackage/3.0/images/masthead_subpage.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="hidden-one" />
	<img src="../../TemplatePackage/3.0/images/masthead_1-col.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="visible-one" />
</a>

<!-- IOS9 iPad bug work around - make sure screen readers have a readable version of the logo to read
<a class="tp-sr-only" href="https://www.cdc.gov">Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People</a>
 -->
                    	</div>
                    	<!-- search -->
                    	<div id="searchArea" class="span10 hidden-one hidden-two">							
							
<div class="hidden"><a href="gonorrhea.htm#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper ">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="">Search The CDC</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>							<div class="a2z-button pull-right hidden-one hidden-two"><a href="gonorrhea.htm#" id="azTab">CDC A-Z Index <span class="icon-angle-down"></span></a></div>
                    	</div>
                    </div>
                    	<div class="hidden-three hidden-four" id="mobile-menu">
		<ul>
			<li id="vp1-menu-button" class="border-bottom-white"><a href="gonorrhea.htm#" id="menu-nav"><span class="sprite-16-menu"></span>MENU</a></li>
			<li id="vp1-a2z-button" class="border-bottom-white"><a href="gonorrhea.htm#" id="menu-az">CDC A-Z</a></li>
			<li id="vp1-search-button" class="border-bottom-white"><a href="gonorrhea.htm#" id="menu-search"><span class="sprite-16-search-white"></span>SEARCH</a></li>
		</ul>
	</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.menu_load = Date.now(); }</script>
                    <div class="a2z-bar hide">
                    	<div>
	<ul>
		<li><a href="../../az/a.html">A</a></li>
		<li><a href="../../az/b.html">B</a></li>
		<li><a href="../../az/c.html">C</a></li>
		<li><a href="../../az/d.html">D</a></li>
		<li><a href="../../az/e.html">E</a></li>
		<li><a href="../../az/f.html">F</a></li>
		<li><a href="../../az/g.html">G</a></li>
		<li><a href="../../az/h.html">H</a></li>
		<li><a href="../../az/i.html">I</a></li>
		<li><a href="../../az/j.html">J</a></li>
		<li><a href="../../az/k.html">K</a></li>
		<li><a href="../../az/l.html">L</a></li>
		<li><a href="../../az/m.html">M</a></li>
		<li><a href="../../az/n.html">N</a></li>
		<li><a href="../../az/o.html">O</a></li>
		<li><a href="../../az/p.html">P</a></li>
		<li><a href="../../az/q.html">Q</a></li>
		<li><a href="../../az/r.html">R</a></li>
		<li><a href="../../az/s.html">S</a></li>
		<li><a href="../../az/t.html">T</a></li>
		<li><a href="../../az/u.html">U</a></li>
		<li><a href="../../az/v.html">V</a></li>
		<li><a href="../../az/w.html">W</a></li>
		<li><a href="../../az/x.html">X</a></li>
		<li><a href="../../az/y.html">Y</a></li>
		<li><a href="../../az/z.html">Z</a></li>
		<li><a href="../../az/0.html">#</a></li>
	</ul>
</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.a2z_load = Date.now(); }</script>                    </div>
                    <div id="searchArea-two-column" class="span24 searchbar hide hidden-three hidden-four">
						  
<div class="hidden"><a href="gonorrhea.htm#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper ">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="">Search The CDC</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>					</div>
                    <!--
	See the noscript include for modifying the emergency message. DO NOT add it here.
-->
<script>if (typeof page_timing !== 'undefined') { page_timing.emergency_load = Date.now(); }</script>
    				<div class="titlebar">
					 						<h2>


<a href="default.htm">2015 Sexually Transmitted Diseases Treatment Guidelines</a>

</h2>
					 					</div>
    				<!-- emergency -->
<div id="emergencyContainer">
	<!--
	<div class="alert alert-error en">
		<b>Attention!</b> Uncomment this section and place the emergency message here.
	</div>
	<div class="alert alert-error esp">
		<b>&#161;Atenci&#243;n!</b> Elimine el comentario de esta secci&#243;n y colocar el mensaje de emergencia aqu&#237;.
	</div>	
	-->
</div>

<!-- no script -->
<noscript>
	<div class="alert alert-block"> Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: <a href="../../other/about_cdcgov.html">About CDC.gov</a>.</div>
</noscript>
<script>if (typeof page_timing !== 'undefined') { page_timing.noscript_load = Date.now(); }</script>
     			</div>
    		</header>
    		<div class="container">				
                <div id="content">
					<div class="row">
        				<!-- left nav -->
        				<div id="nav-container" class="hidden-one hidden-two span5">
    						<nav id="left" class="hidden-one hidden-two">
    							



<h3><a href="default.htm">2015 STD Treatment Guidelines</a></h3>

<ul id="nav-primary">
<li><a href="https://www.cdc.gov/std/tg2015/toc.htm">Table of Contents</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/intro.htm">Introduction and Methods</a></li>

<li><a href="clinical.htm">Clinical Prevention Guidance</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/specialpops.htm">Special Populations</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/emerging.htm">Emerging Issues</a></li>

<li><a href="hiv.htm">HIV Infection: Detection,Counseling and Referral</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/genital-ulcers.htm">Diseases Characterized by Genital, Anal, or Perianal Ulcers</a>
<ul>
<li><a href="https://www.cdc.gov/std/tg2015/chancroid.htm">Chancroid</a></li>

<li><a href="herpes.htm">Genital HSV Infections</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/donovanosis.htm">Granuloma Inguinale (Donovanosis)</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/lgv.htm">Lymphogranuloma Venereum (LGV)</a></li>
</ul>
</li>

<li><a href="https://www.cdc.gov/std/tg2015/syphilis.htm">Syphilis</a>
<ul>
<li><a href="https://www.cdc.gov/std/tg2015/syphilis-pregnancy.htm">Syphilis During Pregnancy</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/congenital.htm">Congenital Syphilis</a></li>
</ul>
</li>

<li><a href="https://www.cdc.gov/std/tg2015/pen-allergy.htm">Management of Persons Who Have a History of Penicillin Allergy</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/urethritis-and-cervicitis.htm">Diseases Characterized by Urethritis and Cervicitis</a></li>

<li><a href="chlamydia.htm">Chlamydial Infections</a></li>

<li><a href="gonorrhea.htm">Gonococcal Infections</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/vaginal-discharge.htm">Diseases Characterized by Vaginal Discharge</a>
<ul id="nav-primary">
<li><a href="bv.htm">Bacterial Vaginosis</a></li>

<li><a href="trichomoniasis.htm">Trichomoniasis</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/candidiasis.htm">Vulvovaginal Candidiasis</a></li>
</ul>
</li>

<li><a href="https://www.cdc.gov/std/tg2015/pid.htm">Pelvic Inflammatory Disease (PID)</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/epididymitis.htm">Epididymitis</a></li>

<li><a href="hpv.htm">Human Papillomavirus (HPV) Infection</a></li>

<li><a href="warts.htm">Anogenital Warts</a></li>

<li><a href="hpv-cancer.htm">HPV-Associated Cancers and Precancers</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/hepatitis.htm">Viral Hepatitis</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/proctitis.htm">Proctitis, Proctocolitis, and Enteritis</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/ectoparasitic.htm">Ectoparasitic Infections</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/sexual-assault.htm">Sexual Assault and Abuse and STDs</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/references.htm">References</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/terms.htm">Terms and Abbreviations Used in This Report</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/consultants.htm">Consultants</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/evidence.htm">Evidence Tables</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/screening-recommendations.htm">Screening Recommendations Referenced in Treatment Guidelines and Original Recommendation Sources</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/default.htm">Questions and Answers</a>
<ul id="nav-primary">
<li><a href="https://www.cdc.gov/std/tg2015/qa/bv-qa.htm">Bacterial Vaginosis (BV)</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/chlamydia-qa.htm">Chlamydia</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/gonorrhea-qa.htm">Gonorrhea</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/herpes-qa.htm">Herpes</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/hpv-qa.htm">HPV</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/mycoplasma-genitaliumqa.htm"><em>Mycoplasma genitalium</em></a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/screening-qa.htm">Screening</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/sexual-assault-qa.htm">Sexual Assault</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/syphilis-qa.htm">Syphilis</a></li>

<li><a href="https://www.cdc.gov/std/tg2015/qa/trichomoniasis-qa.htm">Trichomoniasis</a></li>
</ul>
</li>
</ul>


    						</nav>
    						<div class="nav-related">
							



    						



<div class="module-typeH">
<h3><a href="../default.htm">STDs Home Page</a></h3>

<ul class="list-block">
<li><a href="../treatment/default.htm">Treatment</a></li>
</ul>
</div>

<div class="module-typeH">
<h3>Follow STD</h3>

<ul class="list-block">
<li><a href="https://twitter.com/CDCSTD"><span class="sprite-32-twitter"><!-- marker --></span>STD on Twitter</a></li>

<li style=" text-align: left;"><a href="https://www.facebook.com/CDCSTD"><span class="sprite-32-facebook"><!-- marker --></span>STD on Facebook</a></li>
</ul>
</div>


							



							</div>    						    				
        				</div>
        				<div id="featureArea">
    						<div class="span19">
    							



    						</div>
        				</div>						
    					<div class="breadcrumbs hidden-one span19">
    						


<div class="bread-crumb hidden-one"><div class="prefix"><span><a href="../treatment/default.htm">Treatment</a></span> <span><a href="../default.htm">Sexually Transmitted Diseases</a></span></div></div>

    					</div>
						<div class="span19 pagetitle">	
    						    						    							<div class='mSyndicate'>
    																					<h1>Gonococcal Infections</h1>
															    						    						    							</div>
    												</div>
						<div id="share-bar" class="span19">		
    						<div class="socialmediabar">
								<div class="row">
            						<div class="hidden-one pull-right">
        								            							            							            						</div>	
    								<div class="span8">
    									<div id="socialMediaShareContainer">
	<div class="share_container noLinking">
	 	<a class="share_button_facebook" title="Facebook" href="gonorrhea.htm#"><span class="tp-sr-only">Recommend on Facebook</span><span id="share_facebook" class="facebookRecommend"> </span></a>
	 	<a class="share_button_twitter" title="Twitter" href="gonorrhea.htm#"><span class="tp-sr-only">Tweet</span><span id="share_twitter" class="twitterTweet"> </span></a>
		<a class="share_button" href="gonorrhea.htm#socialMediaShareContainer" ><img src="../../TemplatePackage/3.0/images/social/addthis-32.png" alt="Share" /><span class="shareButtonEn tp-sr-only" aria-label="Share">Share</span><span class="shareButtonEs tp-sr-only" aria-label="Compartir">Compartir</span></a>
	</div>
</div>

<!-- target anchor for return to top feature in VP1 -->
<a id="content-start" tabindex="-1"></a>
    								</div>
								</div>
    						</div>
    					</div>	
    					<!-- body -->
    					<div id="body" class="span19">
    						<div id="contentArea" >								
        						        														
			<div class="span6 pull-right">
    		<div id="onthispage2" class="module-typeF">
				    			<h4>On this Page</h4>				    			<ul class="list-bullet">
    				    				<li><a href="gonorrhea.htm#adults">Gonococcal Infections in Adolescents and Adults</a></li>    				    				<li><a href="gonorrhea.htm#neonate">Gonococcal Infections Among Neonates</a></li>    				    				<li><a href="gonorrhea.htm#children">Gonococcal Infections Among Infants and Children</a></li>    				    			</ul>
    		</div>
		</div>
	  								        						                                                                                            					            					            						<div class='mSyndicate'>
            					            					        							
<div class="module-typeC span6 pull-right">
<p><br />
<img alt="Notice: There is currently a national shortage of:" src="https://www.cdc.gov/std/treatment/images/drug-notice350.jpg" /></p>

<ul class="list-block">
<li><a href="../treatment/drugnotices/gemifloxacin.htm">Gemifloxacin</a></li>
</ul>
</div>

<h3><a class="onThisPageAnchor" id="adults" name="adults" title="Gonococcal Infections in Adolescents and Adults"> </a>Gonococcal Infections in Adolescents and Adults</h3>

<p>In the United States, an estimated 820,000 new <em>N. gonorrhoeae</em> infections occur each year (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#533">533</a></em>). Gonorrhea is the second most commonly reported communicable disease (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#118">118</a></em>). Urethral infections caused by <em>N. gonorrhoeae</em> among men can produce symptoms that cause them to seek curative treatment soon enough to prevent sequelae, but often not soon enough to prevent transmission to others. Among women, gonococcal infections are commonly asymptomatic or might not produce recognizable symptoms until complications (e.g., PID) have occurred. PID can result in tubal scarring that can lead to infertility and ectopic pregnancy.</p>

<p>Annual screening for <em>N. gonorrhoeae</em> infection is recommended for all sexually active women aged &#60;25 years and for older women at increased risk for infection (e.g., those who have a new sex partner, more than one sex partner, a sex partner with concurrent partners, or a sex partner who has an STI) (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#108">108</a></em>). Additional risk factors for gonorrhea include inconsistent condom use among persons who are not in mutually monogamous relationships, previous or coexisting sexually transmitted infections, and exchanging sex for money or drugs. Clinicians should consider the communities they serve and might opt to consult local public health authorities for guidance on identifying groups at increased risk. Gonococcal infection, in particular, is concentrated in specific geographic locations and communities. Subgroups of MSM are at high risk for gonorrhea infection and should be screened at sites of exposure (see <a href="https://www.cdc.gov/std/tg2015/specialpops.htm#msm">MSM</a>). Screening for gonorrhea in men and older women who are at low risk for infection is not recommended (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#108">108</a></em>). A recent travel history with sexual contacts outside of the United States should be part of any gonorrhea evaluation.</p>

<h4><a id="diag"> </a>Diagnostic Considerations</h4>

<p>Specific microbiologic diagnosis of infection with <em>N. gonorrhoeae</em> should be performed in all persons at risk for or suspected to have gonorrhea; a specific diagnosis can potentially reduce complications, reinfections, and transmission. Culture and NAAT are available for the detection of genitourinary infection with <em>N. gonorrhoeae (<a href="https://www.cdc.gov/std/tg2015/references.htm#394">394</a>)</em>; culture requires endocervical (women) or urethral (men) swab specimens. NAAT allows for the widest variety of FDA-cleared specimen types, including endocervical swabs, vaginal swabs, urethral swabs (men), and urine (from both men and women). However, product inserts for each NAAT manufacturer must be carefully consulted because collection methods and specimen types vary. Culture is available for detection of rectal, oropharyngeal, and conjunctival gonococcal infection, but NAAT is not FDA-cleared for use with these specimens. Some laboratories have met CLIA regulatory requirements and established performance specifications for using NAAT with rectal and oropharyngeal swab specimens that can inform clinical management. Certain NAATs that have been demonstrated to detect commensal <em>Neisseria</em> species might have comparable low specificity when testing oropharyngeal specimens for <em>N gonorrhoeae (<a href="https://www.cdc.gov/std/tg2015/references.htm#394">394</a>)</em>. The sensitivity of NAAT for the detection of <em>N. gonorrhoeae</em> in urogenital and nongenital anatomic sites is superior to culture, but varies by NAAT type (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#394">394</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#505">505-508</a></em>). In cases of suspected or documented treatment failure, clinicians should perform both culture and antimicrobial susceptibility testing because nonculture tests cannot provide antimicrobial susceptibility results. Because <em>N. gonorrhoeae</em> has demanding nutritional and environmental growth requirements, optimal recovery rates are achieved when specimens are inoculated directly and when the growth medium is promptly incubated in an increased CO<sub>2</sub> environment (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#394">394</a></em>). Several non-nutritive swab transport systems are available that might maintain gonococcal viability for up to 48 hours in ambient temperatures (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#534">534-536</a></em>).</p>

<p>Because of its high specificity (&#62;99%) and sensitivity (&#62;95%), a Gram stain of urethral secretions that demonstrates polymorphonuclear leukocytes with intracellular Gram-negative diplococci can be considered diagnostic for infection with <em>N. gonorrhoeae</em> in symptomatic men. However, because of lower sensitivity, a negative Gram stain should not be considered sufficient for ruling out infection in asymptomatic men. Detection of infection using Gram stain of endocervical, pharyngeal, and rectal specimens also is insufficient and is not recommended. MB/GV stain of urethral secretions is an alternative point-of-care diagnostic test with performance characteristics similar to Gram stain. Presumed gonococcal infection is established by documenting the presence of WBC containing intracellular purple diplococci in MB/GV smears.</p>

<h4>Antimicrobial-Resistant <em>N. gonorrhoeae</em></h4>

<p>Gonorrhea treatment is complicated by the ability of <em>N. gonorrhoeae</em> to develop resistance to antimicrobials (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#537">537</a></em>). In 1986, the Gonococcal Isolate Surveillance Project (GISP), a national sentinel surveillance system, was established to monitor trends in antimicrobial susceptibilities of urethral <em>N. gonorrhoeae</em> strains in the United States (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#538">538</a></em>). The epidemiology of antimicrobial resistance guides decisions about gonococcal treatment recommendations and has evolved because of shifts in antimicrobial resistance patterns. In 2007, emergence of fluoroquinolone-resistant <em>N. gonorrhoeae</em> in the United States prompted CDC to cease recommending fluoroquinolones for treatment of gonorrhea, leaving cephalosporins as the only remaining class of antimicrobials available for treatment of gonorrhea in the United States (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#539">539</a></em>). Reflecting concern about emerging gonococcal resistance, CDC’s 2010 STD treatment guidelines recommended dual therapy for gonorrhea with a cephalosporin plus either azithromycin or doxycycline, even if NAAT for <em>C. trachomatis</em> was negative at the time of treatment (<em>1</em>). However, during 2006–2011, the minimum concentrations of cefixime needed to inhibit in vitro growth of the <em>N. gonorrhoeae</em> strains circulating in the United States and many other countries increased, suggesting that the effectiveness of cefixime might be waning (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#118">118</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#540">540</a></em>). In addition, treatment failures with cefixime or other oral cephalosporins have been reported in Asia (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#541">541-544</a></em>), Europe (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#545">545-549</a></em>)<em>,</em> South Africa (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#550">550</a></em>), and Canada (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#551">551,552</a></em>). Ceftriaxone treatment failures for pharyngeal infections have been reported in Australia (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#553">553,554</a></em>), Japan (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#555">555</a></em>), and Europe (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#556">556,557</a></em>). As a result, CDC no longer recommends the routine use of cefixime as a first-line regimen for treatment of gonorrhea in the United States (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#540">540</a></em>). In addition, U.S. gonococcal strains with elevated MICs to cefixime also are likely to be resistant to tetracyclines but susceptible to azithromycin (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#540">540</a></em>). Consequently, only one regimen, dual treatment with ceftriaxone and azithromycin, is recommended for treatment of gonorrhea in the United States. CDC (<a href="https://www.cdc.gov/std/gisp">https://www.cdc.gov/std/gisp</a>) and state health departments can provide the most current information on gonococcal susceptibility.</p>

<p>Criteria for resistance to cefixime and ceftriaxone have not been defined by the Clinical and Laboratory Standards Institute (CLSI). However, isolates with cefixime or ceftriaxone MICs ≥0.5 <em>µ</em>g/mL are considered to have decreased susceptibility (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#558">558</a></em>). In the United States, the proportion of isolates in GISP demonstrating decreased susceptibility to ceftriaxone or cefixime has remained low; during 2013, no isolates with decreased susceptibility (MIC <u>&#62;</u>0.5 ug/mL) to ceftriaxone or cefixime were identified (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#118">118</a></em>). Because increasing MICs might predict the emergence of resistance, GISP established lower cephalosporin MIC breakpoints than those set by CLSI to provide greater sensitivity in detecting declining gonococcal susceptibility for surveillance purposes. The percentage of isolates with cefixime MICs ≥0.25 <em>µ</em>g/mL increased from 0.1% in 2006 to 1.4% in 2011 (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#118">118</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#540">540</a></em>), and declined to 0.4% in 2013 (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#118">118</a></em>). The percentage of isolates with ceftriaxone MICs ≥0.125 <em>µ</em>g/mL increased from &#60;0.1% in 2006 to 0.4% in 2011 and decreased to 0.05% in 2013. Isolates with high-level cefixime and ceftriaxone MICs (cefixime MICs 1.5–8 <em>µ</em>g/mL and ceftriaxone MICs 1.5–4 <em>µ</em>g/mL) have been identified in Japan (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#555">555</a></em>), France (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#549">549</a></em>), and Spain (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#559">559,560</a></em>). Decreased susceptibility of <em>N. gonorrhoeae</em> to cephalosporins and other antimicrobials is expected to continue; state and local surveillance for antimicrobial resistance is crucial for guiding local therapy recommendations (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#537">537</a></em>). Although approximately 3% of all U.S. men who have gonococcal infections are sampled through GISP, surveillance by clinicians also is critical. Clinicians who diagnose <em>N. gonorrhoeae</em> infection in a person with suspected cephalosporin treatment failure should perform culture and antimicrobial susceptibility testing (AST) of relevant clinical specimens, consult an infectious-disease specialist for guidance in clinical management, and report the case to CDC through state and local public health authorities. Isolates should be saved and sent to CDC through local and state public health laboratory mechanisms. Health departments should prioritize notification and culture evaluation for sexual partner(s) of persons with <em>N. gonorrhoeae</em> infection thought to be associated with cephalosporin treatment failure or persons whose isolates demonstrate decreased susceptibility to cephalosporin.</p>

<h4>Dual Therapy for Gonococcal Infections</h4>

<p>On the basis of experience with other microbes that have developed antimicrobial resistance rapidly, a theoretical basis exists for combination therapy using two antimicrobials with different mechanisms of action (e.g., a cephalosporin plus azithromycin) to improve treatment efficacy and potentially slow the emergence and spread of resistance to cephalosporins. Use of azithromycin as the second antimicrobial is preferred to doxycycline because of the convenience and compliance advantages of single-dose therapy and the substantially higher prevalence of gonococcal resistance to tetracycline than to azithromycin among GISP isolates, particularly in strains with elevated cefixime MICs (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#118">118</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#540">540</a></em>). In addition, clinical trials have demonstrated the efficacy of azithromycin 1 g for the treatment of uncomplicated urogenital GC (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#561">561,562</a></em>).</p>

<p>Limited data suggest that dual treatment with azithromycin might enhance treatment efficacy for pharyngeal infection when using oral cephalosporins (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#563">563,564</a></em>). In addition, persons infected with <em>N. gonorrhoeae</em> frequently are coinfected with <em>C. trachomatis</em>; this finding has led to the longstanding recommendation that persons treated for gonococcal infection also be treated with a regimen that is effective against uncomplicated genital <em>C. trachomatis</em> infection, further supporting the use of dual therapy that includes azithromycin (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#565">565</a></em>).</p>

<h4>Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum</h4>

<div class="module-typeF">
<h5><em>Recommended Regimen</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 250 mg IM in a single dose<br />
PLUS</li>

<li><strong>Azithromycin</strong> 1g orally in a single dose</li>
</ul>
</div>

<p>As dual therapy, ceftriaxone and azithromycin should be administered together on the same day, preferably simultaneously and under direct observation. Ceftriaxone in a single injection of 250 mg provides sustained, high bactericidal levels in the blood. Extensive clinical experience indicates that ceftriaxone is safe and effective for the treatment of uncomplicated gonorrhea at all anatomic sites, curing 99.2% of uncomplicated urogenital and anorectal and 98.9% of pharyngeal infections in clinical trials (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#566">566,567</a></em>). No clinical data exist to support use of doses of ceftriaxone &#62;250 mg.</p>

<p>Single-dose injectable cephalosporin regimens (other than ceftriaxone 250 mg IM) that are safe and generally effective against uncomplicated urogenital and anorectal gonococcal infections include ceftizoxime (500 mg IM), cefoxitin (2 g IM with probenecid 1 g orally), and cefotaxime (500 mg IM). None of these injectable cephalosporins offer any advantage over ceftriaxone for urogenital infection, and efficacy for pharyngeal infection is less certain (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#566">566,567</a></em>). Several other antimicrobials are active against <em>N. gonorrhoeae</em>, but none have substantial advantages over the recommended regimen, and efficacy data (especially for pharyngeal infection) are limited.</p>

<div class="module-typeF">
<h5><em>Alternative Regimens</em></h5>

<p>If ceftriaxone is not available:</p>

<ul class="list-block">
<li><strong>Cefixime</strong> 400 mg orally in a single dose<br />
PLUS</li>

<li><strong>Azithromycin</strong> 1 g orally in a single dose</li>
</ul>
</div>

<p>A 400-mg oral dose of cefixime should only be considered as an alternative cephalosporin regimen because it does not provide as high, nor as sustained, bactericidal blood levels as a 250-mg dose of ceftriaxone; further, it demonstrates limited efficacy for treatment of pharyngeal gonorrhea (92.3% cure; 95% confidence interval [CI]&#160;=&#160;74.9%–99.1%); in older clinical studies, cefixime cured 97.5% of uncomplicated urogenital and anorectal gonococcal infections (95% CI&#160;=&#160;95.4%–99.8%) (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#566">566,567</a></em>). The increase in the prevalence of isolates obtained through GISP with elevated cefixime MICs might indicate early stages of development of clinically significant gonococcal resistance to cephalosporins. CDC anticipates that rising cefixime MICs soon will result in declining effectiveness of cefixime for the treatment of urogenital gonorrhea. Furthermore, as cefixime becomes less effective, continued used of cefixime might hasten the development of resistance to ceftriaxone, a safe, well-tolerated, injectable cephalosporin and the last antimicrobial known to be highly effective in a single dose for treatment of gonorrhea at all anatomic sites of infection. Other oral cephalosporins (e.g., cefpodoxime and cefuroxime) are not recommended because of inferior efficacy and less favorable pharmacodynamics (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#566">566</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#568">568</a></em>).</p>

<p>Because of the prevalence of tetracycline resistance among GISP isolates, particularly those with elevated cefixime MICs (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#118">118</a></em>), the use of azithromycin as the second antimicrobial is preferred. However, in the case of azithromycin allergy, doxycycline (100 mg orally twice a day for 7 days) can be used in place of azithromycin as an alternative second antimicrobial when used in combination with ceftriaxone or cefixime.</p>

<p>In a recent clinical trial, dual treatment of uncomplicated, urogenital gonorrhea with single doses of oral gemifloxacin 320 mg plus oral azithromycin 2 g was associated with cure rates of 99.5% (lower one-sided 95% CI bound&#160;=&#160;97.6%), and dual treatment with single doses of intramuscular gentamicin 240 mg plus oral azithromycin 2 g cured 100% of cases (lower one-sided 95% CI bound&#160;=&#160;98.5%) (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#569">569</a></em>). This trial was not powered to provide reliable estimates of the efficacy of these regimens for treatment of rectal or pharyngeal infection, but both regimens cured the few extragenital infections among study participants. Either of these regimens might be considered as alternative treatment options in the presence of cephalosporin allergy. However, gastrointestinal adverse events might limit their use: 7.7% of patients treated with gemifloxacin plus azithromycin and 3.3% of patients treated with gentamicin plus azithromycin vomited within 1 hour of medication administration, necessitating retreatment with a ceftriaxone and azithromycin.</p>

<p>Spectinomycin, which is useful in persons who cannot tolerate cephalosporins, is expensive, has poor efficacy against pharyngeal infection (51.8%; 95% CI&#160;=&#160;38.7%–64.9%) (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#566">566</a></em>), and is not being produced in the United States (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#570">570</a></em>). However, it has been effective in clinical trials, curing 98.2% of uncomplicated urogenital and anorectal gonococcal infections (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#566">566</a></em>). When available, spectinomycin is an effective alternative for the treatment of urogenital and anorectal infection.</p>

<p>Monotherapy with azithromycin 2 g orally as a single dose has been demonstrated to be 99.2% effective against uncomplicated urogenital gonorrhea (95% CI&#160;=&#160;97.3%–99.9%) (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#567">567</a></em>). However, monotherapy is no longer recommended because of concerns over the ease with which <em>N. gonorrhoeae</em> can develop resistance to macrolides, and because several studies have documented azithromycin treatment failures (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#546">546</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#571">571-574</a></em>). Strains of <em>N. gonorrhoeae</em> circulating in the United States are not adequately susceptible to penicillins, tetracyclines, and older macrolides (e.g., erythromycin), and thus use of these antimicrobials cannot be recommended.</p>

<h4>Uncomplicated Gonococcal Infections of the Pharynx</h4>

<p>Most gonococcal infections of the pharynx are asymptomatic and can be relatively common in some populations (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#505">505,506</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#575">575,576</a></em>). Gonococcal infections of the pharynx are more difficult to eradicate than are infections at urogenital and anorectal sites (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#551">551</a></em>). Few antimicrobial regimens, including those involving oral cephalosporins, can reliably cure &#62;90% of gonococcal pharyngeal infections (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#566">566,567</a></em>). Providers should ask their patients with urogenital or rectal GC about oral sexual exposure; if reported, patients should be treated with a regimen with acceptable efficacy against pharyngeal gonorrhea infection.</p>

<div class="module-typeF">
<h5><em>Recommended Regimen</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 250 mg IM in a single dose<br />
PLUS</li>

<li><strong>Azithromycin</strong> 1 g orally in a single dose</li>
</ul>
</div>

<h4>Other Management Considerations</h4>

<p>To maximize adherence with recommended therapies and reduce complications and transmission, medication for gonococcal infection should be provided on site and directly observed. If medications are not available when treatment is indicated, linkage to an STD treatment facility should be provided for same-day treatment. To minimize disease transmission, persons treated for gonorrhea should be instructed to abstain from sexual activity for 7 days after treatment and until all sex partners are adequately treated (7 days after receiving treatment and resolution of symptoms, if present). All persons who receive a diagnosis of gonorrhea should be tested for other STDs, including chlamydia, syphilis, and HIV.</p>

<h4><a id="Follow-Up"> </a>Follow-Up</h4>

<p>A test-of-cure is not needed for persons who receive a diagnosis of uncomplicated urogenital or rectal gonorrhea who are treated with any of the recommended or alternative regimens; however, any person with pharyngeal gonorrhea who is treated with an alternative regimen should return 14 days after treatment for a test-of cure using either culture or NAAT. If the NAAT is positive, effort should be made to perform a confirmatory culture before retreatment. All positive cultures for test-of-cure should undergo antimicrobial susceptibility testing.</p>

<p>Symptoms that persist after treatment should be evaluated by culture for <em>N. gonorrhoeae</em> (with or without simultaneous NAAT), and any gonococci isolated should be tested for antimicrobial susceptibility. Persistent urethritis, cervicitis, or proctitis also might be caused by other organisms (see <a href="https://www.cdc.gov/std/tg2015/urethritis-and-cervicitis.htm">Urethritis, Cervicitis</a>, and <a href="https://www.cdc.gov/std/tg2015/proctitis.htm">Proctitis</a> sections).</p>

<p>A high prevalence of <em>N. gonorrhoeae</em> infection has been observed among men and women previously treated for gonorrhea (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#86">86</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#480">480,481</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#577">577</a></em>). Rather than signaling treatment failure, most of these infections result from reinfection caused by failure of sex partners to receive treatment or the initiation of sexual activity with a new infected partner, indicating a need for improved patient education and treatment of sex partners. Men or women who have been treated for gonorrhea should be retested 3 months after treatment regardless of whether they believe their sex partners were treated. If retesting at 3 months is not possible, clinicians should retest whenever persons next present for medical care within 12 months following initial treatment.</p>

<h4><a id="man-part"> </a>Management of Sex Partners</h4>

<p>Recent sex partners (i.e., persons having sexual contact with the infected patient within the 60 days preceding onset of symptoms or gonorrhea diagnosis) should be referred for evaluation, testing, and presumptive dual treatment. If the patient’s last potential sexual exposure was &#62;60 days before onset of symptoms or diagnosis, the most recent sex partner should be treated. To avoid reinfection, sex partners should be instructed to abstain from unprotected sexual intercourse for 7 days after they and their sexual partner(s) have completed treatment and after resolution of symptoms, if present.</p>

<p>For heterosexual men and women with gonorrhea for whom health department partner-management strategies are impractical or unavailable and whose providers are concerned about partners’ access to prompt clinical evaluation and treatment, EPT with cefixime 400 mg and azithromycin 1 g can be delivered to the partner by the patient, a disease investigation specialist, or a collaborating pharmacy as permitted by law (see <a href="clinical.htm#partner">Partner Services</a>). With this approach, provision of medication must be accompanied by written materials (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#93">93</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#95">95</a></em>) to educate partners about their exposure to gonorrhea, the importance of therapy, and when to seek clinical evaluation for adverse reactions or complications. Educational materials for female partners should include information about the importance of seeking medical evaluation for PID (especially if symptomatic); undertreatment of PID in female partners and missed opportunities to diagnose other STDs in women are of concern. EPT should not be considered a routine partner management strategy in MSM with gonorrhea because of a high risk for coexisting infections (especially HIV infection) and because no data exist on efficacy in this population.</p>

<h4>Special Considerations</h4>

<h5>Allergy, Intolerance, and Adverse Reactions</h5>

<p>Allergic reactions to first-generation cephalosporins occur in &#60;2.5% of persons with a history of penicillin allergy and are uncommon with third-generation cephalosporins (e.g., ceftriaxone and cefixime) (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#428">428</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#430">430</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#464">464</a>)</em>. Use of ceftriaxone or cefixime is contraindicated in persons with a history of an IgE-mediated penicillin allergy (e.g., anaphylaxis, Stevens Johnson syndrome, and toxic epidermal necrolysis) (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#428">428</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#431">431</a></em>). Data are limited regarding alternative regimens for treating gonorrhea among persons who have either a cephalosporin or IgE-mediated penicillin allergy. Potential therapeutic options are dual treatment with single doses of oral gemifloxacin 320 mg plus oral azithromycin 2 g or dual treatment with single doses of intramuscular gentamicin 240 mg plus oral azithromycin 2 g (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#569">569</a></em>). Spectinomycin for treatment of urogenital and anorectal gonorrhea can be considered when available. Providers treating persons with cephalosporin or IgE-mediated penicillin allergy should consult an infectious-disease specialist.</p>

<h5><a id="preg"> </a>Pregnancy</h5>

<p>Pregnant women infected with <em>N. gonorrhoeae</em> should be treated with dual therapy consisting of ceftriaxone 250 mg in a single IM dose and azithromycin 1 g orally as a single dose. When cephalosporin allergy or other considerations preclude treatment with this regimen and spectinomycin is not available, consultation with an infectious-disease specialist is recommended.</p>

<h5>HIV Infection</h5>

<p>Persons who have gonorrhea and HIV infection should receive the same treatment regimen as those who are HIV negative. For more information, see appropriate treatment sections under <a href="gonorrhea.htm">Gonoccocal Infections</a>.</p>

<h5>Suspected Cephalosporin Treatment Failure</h5>

<p>Cephalosporin treatment failure is the persistence of <em>N. gonorrhoeae</em> infection despite appropriate cephalosporin treatment and is indicative of infection with cephalosporin-resistant gonorrhea in persons whose partners were adequately treated and whose risk for reinfection is low. Suspected treatment failure has been reported among persons receiving oral and injectable cephalosporins (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#541">541-557</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#578">578</a></em>). Treatment failure should be considered in 1) persons whose symptoms do not resolve within 3–5 days after appropriate treatment and report no sexual contact during the post-treatment follow-up period and 2) persons with a positive test-of-cure (i.e., positive culture <u>&#62;</u>72 hours or positive NAAT ≥7 days after receiving recommended treatment) when no sexual contact is reported during the post-treatment follow-up period (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#579">579</a></em>). Treatment failure should also be considered in persons who have a positive culture on test-of-cure (if obtained) if there is evidence of decreased susceptibility to cephalosporins on antimicrobial susceptibility testing, regardless of whether sexual contact is reported during the post-treatment follow-up period.</p>

<p>Most suspected treatment failures in the United States are likely to be re-infections rather than actual treatment failures (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#86">86</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#480">480,481</a>,<a href="https://www.cdc.gov/std/tg2015/references.htm#577">577</a></em>). However, in cases where reinfection is unlikely and treatment failure is suspected, before retreatment, relevant clinical specimens should be obtained for culture (preferably with simultaneous NAAT) and antimicrobial susceptibility testing if <em>N. gonorrhoeae</em> is isolated. Phenotypic antimicrobial susceptibility testing should be performed using disk diffusion, Etest (BioMérieux, Durham, NC), or agar dilution. Data are limited on the use of DNA amplification and sequencing for detection of genetic mutations associated with gonococcal antimicrobial resistance. All isolates of suspected treatment failures should be sent to CDC for antimicrobial susceptibility testing by agar dilution; local laboratories should store isolates for possible further testing if needed. Testing and/or storage of specimens or isolates should be facilitated by the state or local health department according to local public health protocol. Instructions for shipping isolates to CDC are available at <a href="https://www.cdc.gov/std/gonorrhea/arg/specimen_shipping_instructions1-29-08.pdf">www.cdc.gov/std/gonorrhea/arg/specimen_shipping_instructions1-29-08.pdf</a>.</p>

<p>For persons with suspected cephalosporin treatment failure, the treating clinician should consult an infectious-disease specialist, an STD/HIV Prevention Training Center clinical expert (<a href="http://www.nnptc.org">http://www.nnptc.org</a>), the local or state health department STD program, or CDC (telephone: 404–639–8659) for advice on obtaining cultures, antimicrobial susceptibility testing, and treatment. Suspected treatment failure should be reported to CDC through the local or state health department within 24 hours of diagnosis.</p>

<p>Suspected treatment failures first should be retreated routinely with the recommended regimen (ceftriaxone 250 mg IM plus azithromycin 1 g orally), because reinfections are more likely than actual treatment failures. However, in situations with a higher likelihood of treatment failure than reinfection, relevant clinical specimens should be obtained for culture (preferably with simultaneous NAAT) and antimicrobial susceptibility testing performed before retreatment. Dual treatment with single doses of oral gemifloxacin 320 mg plus oral azithromycin 2 g or dual treatment with single doses of intramuscular gentamicin 240 mg plus oral azithromycin 2 g can be considered, particularly when isolates are found to have elevated cephalosporin MICs (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#569">569</a></em>). Persons with suspected treatment failure after treatment with the alternative regimen (cefixime and azithromycin) should be treated with ceftriaxone 250 mg as a single IM dose and azithromycin 2 g orally as a single dose. A test-of-cure at relevant clinical sites should be obtained 7–14 days after retreatment; culture is the recommended test, preferably with simultaneous NAAT and antimicrobial susceptibility testing of <em>N gonorrhoeae</em> if isolated. Clinicians should ensure that the patient’s sex partners from the preceding 60 days are evaluated promptly with culture and presumptively treated using the same regimen used for the patient.</p>

<h4>Gonococcal Conjunctivitis</h4>

<p>In the only published study (conducted in 1989) of the treatment of gonococcal conjunctivitis among adults, all 12 study participants responded to a single 1-g IM injection of ceftriaxone (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#580">580</a></em>). On the basis of experience with other microbes that have developed antimicrobial resistance rapidly, a theoretical basis exists for combination therapy using two antimicrobials with different mechanisms of action (e.g., a cephalosporin plus azithromycin) to improve treatment efficacy and potentially slow the emergence and spread of resistance to cephalosporins. Because gonococcal conjunctivitis is uncommon and data on treatment of gonococcal conjunctivitis in adults are limited, consultation with an infectious-disease specialist should be considered.</p>

<div class="module-typeF">
<h5><em>Recommended Regimen</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 1 g IM in a single dose<br />
PLUS</li>

<li><strong>Azithromycin</strong> 1 g orally in a single dose</li>
</ul>
</div>

<p>Consider one-time lavage of the infected eye with saline solution.</p>

<h5>Management of Sex Partners</h5>

<p>Patients should be instructed to refer their sex partners for evaluation and treatment. For more information, see Gonococcal Infections, Management of Sex Partners.</p>

<h4><a id="dgi"> </a>Disseminated Gonococcal Infection</h4>

<p>Disseminated gonococcal infection (DGI) frequently results in petechial or pustular acral skin lesions, asymmetric polyarthralgia, tenosynovitis, or oligoarticular septic arthritis (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#581">581</a></em>). The infection is complicated occasionally by perihepatitis and rarely by endocarditis or meningitis. Some strains of <em>N. gonorrhoeae</em> that cause DGI can cause minimal genital inflammation. If DGI is suspected, NAAT or culture specimens from urogenital and extragenital sites, as applicable, should be collected and processed in addition to specimens from disseminated sites of infection (e.g., skin, synovial fluid, blood, and the CNS). All <em>N. gonorrhoeae</em> isolates should be tested for antimicrobial susceptibility.</p>

<p>Hospitalization and consultation with an infectious-disease specialist are recommended for initial therapy, especially for persons who might not comply with treatment, have an uncertain diagnosis, or have purulent synovial effusions or other complications. Examination for clinical evidence of endocarditis and meningitis should be performed.</p>

<h5>Treatment of Arthritis and Arthritis-Dermatitis Syndrome</h5>

<div class="module-typeF">
<h5><em>Recommended Regimen</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 1 g IM or IV every 24 hours<br />
PLUS</li>

<li><strong>Azithromycin</strong> 1 g orally in a single dose</li>
</ul>

<h5><em>Alternative Regimens</em></h5>

<ul class="list-block">
<li><strong>Cefotaxime</strong> 1 g IV every 8 hours<br />
OR</li>

<li><strong>Ceftizoxime</strong> 1 g IV every 8 hours<br />
PLUS</li>

<li><strong>Azithromycin</strong> 1 g orally in a single dose</li>
</ul>
</div>

<p>When treating for the arthritis-dermatitis syndrome, the provider can switch to an oral agent guided by antimicrobial susceptibility testing 24–48 hours after substantial clinical improvement, for a total treatment course of at least 7 days.</p>

<h5>Treatment of Gonococcal Meningitis and Endocarditis</h5>

<div class="module-typeF">
<h5><em>Recommended Regimen</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 1–2 g IV every 12–24 hours<br />
PLUS</li>

<li><strong>Azithromycin</strong> 1 g orally in a single dose</li>
</ul>
</div>

<p>No recent studies have been published on the treatment of DGI. The duration of treatment of DGI has not been systematically studied and should be determined in consultation with an infectious-disease specialist. Treatment for DGI should be guided by the results of antimicrobial susceptibility testing. Pending antimicrobial susceptibility results, treatment decisions should be made on the basis of clinical presentation. Therapy for meningitis should be continued with recommended parenteral therapy for 10–14 days. Parenteral antimicrobial therapy for endocarditis should be administered for at least 4 weeks.</p>

<h5>Management of Sex Partners</h5>

<p>Gonococcal infection frequently is asymptomatic in sex partners of persons who have DGI. Providers should instruct patients to refer partners with whom they have had sexual contact in the past 60 days for evaluation, testing, and presumptive treatment (see Gonococcal Infection, <a href="gonorrhea.htm#man-part">Management of Sex Partners</a>).</p>

<p style=" text-align: right;"><span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="gonorrhea.htm#">Top of Page</a></span></p>

<h3><a class="onThisPageAnchor" id="neonate" name="neonate" title="Gonococcal Infections Among Neonates"> </a>Gonococcal Infections Among Neonates</h3>

<p>Prenatal screening and treatment of pregnant women is the best method for preventing GC infection among neonates. Gonococcal infection among neonates results from perinatal exposure to the mother’s infected cervix. It is usually an acute illness that manifests 2–5 days after birth. The prevalence of infection among infants depends on the prevalence of infection among pregnant women, whether pregnant women are screened and treated for gonorrhea, and whether newborns receive ophthalmia prophylaxis. The most severe manifestations of <em>N. gonorrhoeae</em> infection in newborns are ophthalmia neonatorum and sepsis, which can include arthritis and meningitis. Less severe manifestations include rhinitis, vaginitis, urethritis, and infection at sites of fetal monitoring.</p>

<h4><a id="op-neo"> </a>Ophthalmia Neonatorum Prophylaxis</h4>

<p>To prevent gonococcal ophthalmia neonatorum, a prophylactic agent should be instilled into both eyes of all newborn infants; this procedure is required by law in most states. Ocular prophylaxis is warranted because it can prevent sight-threatening gonococcal ophthalmia, has an excellent safety record, is easy to administer, and is inexpensive. The recommended prophylactic regimen prevents gonococcal ophthalmia; however, its efficacy for prevention of chlamydial ophthalmia is less clear, and it does not eliminate nasopharyngeal colonization by <em>C. trachomatis</em>.</p>

<div class="module-typeF">
<h5><em>Recommended Regimen</em></h5>

<ul class="list-block">
<li><strong>Erythromycin</strong> (0.5%) ophthalmic ointment in each eye in a single application at birth</li>
</ul>
</div>

<p>This preparation should be instilled into both eyes of all neonates as soon as possible after delivery, regardless of whether they are delivered vaginally or by cesarean section. Ideally, ointment should be applied using single-use tubes or ampules rather than multiple-use tubes. If prophylaxis is delayed (i.e., not administered in the delivery room), a monitoring system should be established to ensure that all infants receive prophylaxis.</p>

<p>Erythromycin is the only antibiotic ointment recommended for use in neonates. Silver nitrate and tetracycline ophthalmic ointment is no longer manufactured in the United States, bacitracin is not effective, and povidone iodine has not been studied adequately (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#582">582,583</a></em>). Gentamicin ophthalmic ointment has been associated with severe ocular reactions in neonates and should not be used for ocular prophylaxis (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#584">584,585</a></em>). If erythromycin ointment is not available, infants at risk for exposure to <em>N. gonorrhoeae</em> (especially those born to a mother at risk for gonococcal infection or with no prenatal care) can be administered ceftriaxone 25–50 mg/kg IV or IM, not to exceed 125 mg in a single dose (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#586">586</a></em>).</p>

<p><em>N. gonorrhoeae</em> causes ophthalmia neonatorum relatively infrequently in the United States (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#587">587</a></em>). However, identifying and treating this infection is especially important, because ophthalmia neonatorum can result in perforation of the globe of the eye and blindness (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#588">588</a></em>).</p>

<h4>Diagnostic Considerations</h4>

<p>Infants at increased risk for gonococcal ophthalmia include those who did not receive ophthalmia prophylaxis and whose mothers had no prenatal care or have a history of STDs or substance abuse. Gonococcal ophthalmia is strongly suspected when intracellular gram-negative diplococci are identified on Gram stain of conjunctival exudate, justifying presumptive treatment for gonorrhea after appropriate cultures and antimicrobial susceptibility testing for <em>N. gonorrhoeae</em> are performed. Presumptive treatment for <em>N. gonorrhoeae</em> might be indicated for newborns at increased risk for gonococcal ophthalmia who have increased WBCs (but not intracellular gram negative diplococci) in a Gram-stained smear of conjunctival exudate. Nongonococcal causes of neonatal ophthalmia include <em>Moraxella catarrhalis</em> and other Neisseria species, organisms that are indistinguishable from <em>N. gonorrhoeae</em> on Gram-stained smear but can be differentiated in the microbiology laboratory.</p>

<h4>Treatment</h4>

<div class="module-typeF">
<h5><em>Recommended Regimen</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 25–50 mg/kg IV or IM in a single dose, not to exceed 125 mg</li>
</ul>
</div>

<p>One dose of ceftriaxone is adequate therapy for gonococcal conjunctivitis. Ceftriaxone should be administered cautiously to hyperbilirubinemic infants, especially those born prematurely. No data exist on the use of dual therapy for the treatment of gonococcal ophthalmia. Topical antibiotic therapy alone is inadequate and unnecessary if systemic treatment is administered.</p>

<h4>Other Management Considerations</h4>

<p>Appropriate chlamydial testing should be done simultaneously from the inverted eyelid specimen (see <a href="chlamydia.htm#op-neo">Ophthalmia Neonatorum Caused by</a> <em><a href="chlamydia.htm#op-neo">C. trachomatis</a></em>). Infants who have gonococcal ophthalmia should be evaluated for signs of disseminated infection (e.g., sepsis, arthritis, and meningitis). Infants who have gonococcal ophthalmia should be managed in consultation with an infectious-disease specialist.</p>

<h4>Follow-up</h4>

<p>Infants who have ophthalmia neonatorum should be managed in consultation with an infectious-disease specialist.</p>

<h4>Management of Mothers and Their Sex Partners</h4>

<p>Mothers of infants with ophthalmia neonatorum caused by <em>N. gonorrhoeae</em> should be evaluated, tested, and presumptively treated for gonorrhea, along with their sex partner(s). For more information, see <a href="gonorrhea.htm#adults">Gonococcal Infections in Adolescents and Adults</a>.</p>

<h4>DGI and Gonococcal Scalp Abscesses in Neonates</h4>

<p>DGI might present as sepsis, arthritis, or meningitis and is a rare complication of neonatal gonococcal infection. Localized gonococcal infection of the scalp can result from fetal monitoring through scalp electrodes. Detection of gonococcal infection in neonates who have sepsis, arthritis, meningitis, or scalp abscesses requires cultures of blood, CSF, and joint aspirate. Specimens obtained from the conjunctiva, vagina, oropharynx, and rectum are useful for identifying the primary site(s) of infection. Antimicrobial susceptibility testing of all isolates should be performed. Positive Gram-stained smears of exudate, CSF, or joint aspirate provide a presumptive basis for initiating treatment for <em>N. gonorrhoeae</em>.</p>

<div class="module-typeF">
<h5><em>Recommended Regimens</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 25–50 mg/kg/day IV or IM in a single daily dose for 7 days, with a duration of 10–14 days if meningitis is documented<br />
OR</li>

<li><strong>Cefotaxime</strong> 25 mg/kg IV or IM every 12 hours for 7 days, with a duration of 10–14 days if meningitis is documented</li>
</ul>
</div>

<p>Ceftriaxone should be administered cautiously to hyperbilirubinemic infants, especially those born prematurely. No data exist on the use of dual therapy for the treatment of DGI or gonococcal scalp abscesses.</p>

<h4>Other Management Considerations</h4>

<p>Appropriate chlamydial testing should be done simultaneously in neonates with gonococcal infection. For more information, see <a href="chlamydia.htm#neonates">Chlamydia Infection in Neonates</a>. Infants who have DGI should be managed in consultation with an infectious-disease specialist.</p>

<h4>Management of Mothers and Their Sex Partners</h4>

<p>Mothers of infants who have DGI or scalp abscesses caused by <em>N. gonorrhoeae</em> should be evaluated, tested, and presumptively treated for gonorrhea, along with their sex partner(s). For more information, see <a href="gonorrhea.htm#adults">Gonococcal Infections in Adolescents and Adults</a>.</p>

<h4>Neonates Born to Mothers Who Have Gonococcal Infection</h4>

<p>Neonates born to mothers who have untreated gonorrhea are at high risk for infection. Neonates should be tested for gonorrhea at exposed sites and treated presumptively for gonorrhea as recommended in these guidelines. No data exist on the use of dual therapy to treat neonates born to mothers who have gonococcal infection.</p>

<div class="module-typeF">
<h5><em>Recommended Regimen in the Absence of Signs of Gonococcal Infection</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 25–50 mg/kg IV or IM in a single dose, not to exceed 125 mg</li>
</ul>
</div>

<h5>Other Management Considerations</h5>

<p>Appropriate chlamydial testing should be done simultaneously in neonates with gonococcal infection. For more information, see <a href="chlamydia.htm#neonates">Chlamydia Infection in Neonates</a>. Follow-up examination is not required.</p>

<h5>Management of Mothers and Their Sex Partners</h5>

<p>Mothers who have gonorrhea and their sex partners should be evaluated, tested, and presumptively treated for gonorrhea. For more information, see <a href="gonorrhea.htm">Gonococcal Infections</a>.</p>

<p style=" text-align: right;"><span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="gonorrhea.htm#">Top of Page</a></span></p>

<h3><a class="onThisPageAnchor" id="children" name="children" title="Gonococcal Infections Among Infants and Children"> </a>Gonococcal Infections Among Infants and Children</h3>

<p>Sexual abuse is the most frequent cause of gonococcal infection in infants and children (see <a href="https://www.cdc.gov/std/tg2015/sexual-assault.htm#children">Sexual Assault or Abuse of Children</a>). For preadolescent girls, vaginitis is the most common manifestation of this infection; gonococcal-associated PID after vaginal infection can be less common in preadolescents than adults. Among sexually abused children, anorectal and pharyngeal infections with <em>N. gonorrhoeae</em> are frequently asymptomatic.</p>

<h4>Diagnostic Considerations</h4>

<p>NAAT can be used to test vaginal and urine specimens from girls (see <a href="https://www.cdc.gov/std/tg2015/sexual-assault.htm#children">Sexual Assault or Abuse of Children</a>), although data are insufficient to recommend the use of these tests in boys and from extragenital sites (rectum and pharynx) in boys and girls (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#394">394</a></em>). Culture remains the preferred method for diagnosing boys and for detecting infection in specimens obtained from extragenital sites regardless of gender (<em><a href="https://www.cdc.gov/std/tg2015/references.htm#394">394</a></em>). Gram stains are inadequate for evaluating prepubertal children for gonorrhea and should not be used to diagnose or exclude gonorrhea. If evidence of disseminated gonococcal infection exists, gonorrhea culture and antimicrobial susceptibility testing should be obtained from relevant clinical sites (see <a href="gonorrhea.htm#dgi">DGI</a>).</p>

<div class="module-typeF">
<h5><em>Recommended Regimen for Infants and Children Who Weigh ≤45 kg and Who Have Uncomplicated Gonococcal Vulvovaginitis, Cervicitis, Urethritis, Pharyngitis, or Proctitis</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 25–50 mg/kg IV or IM in a single dose, not to exceed 125 mg IM</li>
</ul>

<h5><em>Recommended Regimen for Children Who Weigh &#62;45 kg and Who Have Uncomplicated Gonococcal Vulvovaginitis, Cervicitis, Urethritis, Pharyngitis, or Proctitis</em></h5>

<ul class="list-block">
<li>Treat with one of the regimens recommended for adults (see Gonococcal Infections)</li>
</ul>

<h5><em>Recommended Regimen for Children Who Weigh ≤45 kg and Who Have Bacteremia or Arthritis</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 50 mg/kg (maximum dose: 1 g) IM or IV in a single dose daily for 7 days</li>
</ul>

<h5><em>Recommended Regimen for Children Who Weigh &#62;45 kg and Who Have Bacteremia or Arthritis</em></h5>

<ul class="list-block">
<li><strong>Ceftriaxone</strong> 1 g IM or IV in a single dose daily every 24 hours for 7 days</li>
</ul>
</div>

<p>No data exist regarding the use of dual therapy for treating children with gonococcal infection.</p>

<h4>Other Management Considerations</h4>

<p>Follow-up cultures are unnecessary. Only parenteral cephalosporins (i.e., ceftriaxone) are recommended for use in children. All children found to have gonococcal infections should be tested for <em>C. trachomatis</em>, syphilis, and HIV. For a discussion of concerns regarding sexual assault, see <a href="https://www.cdc.gov/std/tg2015/sexual-assault.htm#children">Sexual Assault or Abuse of Children</a>.</p>

<p style=" text-align: right;"><span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="gonorrhea.htm#">Top of Page</a></span></p>



<p style=" text-align: right;"><a href="https://www.cdc.gov/std/tg2015/vaginal-discharge.htm">Next</a></p>
             					            					            					            						</div>
            													        						                                                                                        						                                                                								<!-- Related Nav Area -->
								<div class="nav-related hidden-three hidden-four">
									



									



<div class="module-typeH">
<h3><a href="../default.htm">STDs Home Page</a></h3>

<ul class="list-block">
<li><a href="../treatment/default.htm">Treatment</a></li>
</ul>
</div>

<div class="module-typeH">
<h3>Follow STD</h3>

<ul class="list-block">
<li><a href="https://twitter.com/CDCSTD"><span class="sprite-32-twitter"><!-- marker --></span>STD on Twitter</a></li>

<li style=" text-align: left;"><a href="https://www.facebook.com/CDCSTD"><span class="sprite-32-facebook"><!-- marker --></span>STD on Facebook</a></li>
</ul>
</div>


								</div>
    							<!-- Persistent Content Area -->
    							<div id="content-secondary">
                                    



            						



    							</div><!-- /end #content-secondary -->
    						</div><!-- /end #contentArea -->
    					</div><!-- /end body -->	
					</div>
					<div class="row">
						<div class="span24 visible-one">
																											</div>
					</div>
					<div class="row">
						<div class="span24">
                            <div id="plugin-legend" class="pluginOff">
	<h5>File Formats Help:</h5><span><a href="../../Other/plugins/index.html">How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?</a></span>
	<ul>
		<li class="plugin-pdf"><a href="../../Other/plugins/index.html#pdf"><span class="sprite-16-pdf">Adobe PDF file</span></a></li>
		<li class="plugin-ppt"><a href="../../Other/plugins/index.html#ppt"><span class="sprite-16-ppt">Microsoft PowerPoint file</span></a></li>
		<li class="plugin-word"><a href="../../Other/plugins/index.html#doc"><span class="sprite-16-word">Microsoft Word file</span></a></li>
		<li class="plugin-excel"><a href="../../Other/plugins/index.html#xls"><span class="sprite-16-excel">Microsoft Excel file</span></a></li>
		<li class="plugin-wmv"><a href="../../Other/plugins/index.html#wmv"><span class="sprite-16-wmv">Audio/Video file</span></a></li>
		<li class="plugin-qt"><a href="../../Other/plugins/index.html#qt"><span class="sprite-16-qt">Apple Quicktime file</span></a></li>
		<li class="plugin-real"><a href="../../Other/plugins/index.html#ram"><span class="sprite-16-rp">RealPlayer file</span></a></li>
		<li class="plugin-text"><a href="../../Other/plugins/index.html#text"><span class="sprite-16-txt">Text file</span></a></li>
		<li class="plugin-zip"><a href="../../Other/plugins/index.html#zip"><span class="sprite-16-zip">Zip Archive file</span></a></li>
		<li class="plugin-sas"><a href="../../Other/plugins/index.html#sas"><span class="sprite-16-sas">SAS file</span></a></li>
		<li class="plugin-epub"><a href="../../Other/plugins/index.html#epub"><span class="sprite-16-ebook">ePub file</span></a></li>
		<li class="plugin-ris"><a href="../../Other/plugins/index.html#ris"><span class="sprite-16-ris">RIS file</span></a></li>
	</ul>
</div>
						</div>
					</div>
					<!-- date stamp -->
					<div id="datestamp" class="row" itemscope="itemscope" itemtype="http://schema.org/WebPage">
						<div class="span24">
    						<ul> 
            					            						<li class="last-reviewed">Page last reviewed: <span itemprop="lastReviewed">June 4, 2015</span></li>
            													            					            						<li class="last-updated">Page last updated: <span itemprop="dateModified">July 27, 2016</span></li>
            					        							<li class="content-source">Content source:
    									


<ul class="noindent"><li class="" itemprop="sourceOrganization" itemscope="itemscope" itemtype="http://schema.org/Organization"><a href="../dstdp.1.html" itemprop="url">Division of STD Prevention</a>, <a href="../../nchhstp.1.html" itemprop="url">National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention</a>, <a href="../../index.html" itemprop="url">Centers for Disease Control and Prevention</a></li></ul>

        							</li>
									



    						</ul>
						</div>
					</div>					
				</div><!-- /end #content -->
			</div><!-- /.container for content -->					
			<!-- footer -->
				<footer id="footer" class="cdcSlimFooter">
	
 <!-- include eng footerSubSocialMedia.html -->
<div class="socialMedia">
	<div class="container">
		<nav class="followcdc">
			<ul>
				<li><a href="../../Other/emailupdates.1.html"><span class="sprite-24-govd"></span><span class="tp-sr-only">Email</span></a></li>
				<li><a href="https://www.facebook.com/CDC" target="_blank"><span class="sprite-24-facebook"></span><span class="tp-sr-only">Recommend</span></a></li>
				<li><a href="https://twitter.com/CDCgov" target="_blank"><span class="sprite-24-twitter"></span><span class="tp-sr-only">Tweet</span></a></li>
				<li><a href="https://www.youtube.com/user/CDCstreamingHealth" target="_blank"><span class="sprite-24-youtube"></span><span class="tp-sr-only">YouTube</span></a></li>
				<li><a href="https://www.instagram.com/CDCgov/" target="_blank"><span class="sprite-24-instagram"></span><span class="tp-sr-only">Instagram</span></a></li>
			</ul>
		</nav>
		<nav class="cdcmedia">
			<ul>
				<li><a href="https://www2c.cdc.gov/podcasts"><span class="sprite-24-listen"></span><span class="tp-sr-only">Listen</span></a></li>
				<li><a href="../../cdctv.1.html"><span class="sprite-24-watch"></span><span class="tp-sr-only">Watch</span></a></li>
				<li><a href="https://www2c.cdc.gov/podcasts/rss.asp"><span class="sprite-24-rss"></span><span class="tp-sr-only">RSS</span></a></li>
			</ul>
		</nav>
	</div>
</div>
 <!-- /include eng footerSubSocialMedia.html -->

	<div class="container">
		<div class="cdcLinks">
			<div class="container">
				<ul>
					
<!-- include eng footerSubCdcLinks.html-->
<li>
	<nav>
		<h6 class="hidden-four hidden-three">ABOUT <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../about/default.htm">About CDC</a></li>
			<li><a href="https://jobs.cdc.gov">Jobs</a></li>
			<li><a href="../../funding.1.html">Funding</a></li>
		</ul>
	</nav>
</li>
<li>
	<nav>
		<h6 class="hidden-four hidden-three">LEGAL <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../Other/policies.html">Policies</a></li>
			<li><a href="../../Other/privacy.html">Privacy</a></li>
			<li><a href="../../od/foia.1.html">FOIA</a></li>
			<li><a href="../../eeo/nofearact/index.htm">No Fear Act</a></li>
			<li><a href="https://oig.hhs.gov" class="no-link">OIG</a></li>
		</ul>
	</nav>
</li>
<!--/ include eng footerSubCdcLinks.html-->

				</ul>
			</div>
		</div>
		<div class="cdcContact">
			<div class="container">
				<ul>
					<li class="local-contact">
						
 <!-- include eng footerSubGlobalContact1.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="address" itemscope="itemscope" itemtype="https://schema.org/PostalAddress">
			<span itemprop="streetAddress">1600 Clifton Road</span>
			<span itemprop="addressLocality">Atlanta</span>,
			<span itemprop="addressRegion">GA</span>
			<span itemprop="postalCode">30329-4027</span>
			<span itemprop="addressCountry">USA</span>
		</span><br />
		<span class="value" itemprop="telephone">800-CDC-INFO (800-232-4636)</span>,
		<span class="value" itemprop="telephone">TTY: 888-232-6348</span><br />
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://wwwn.cdc.gov/dcs/RequestForm.aspx" class=" default no-link">Email CDC-INFO</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact1.html -->

					</li>
					<li class="contact">
						
 <!-- include eng footerSubGlobalContact2.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.hhs.gov" class="no-link">U.S. Department of Health & Human Services</a></span>
		</span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
        	<span itemprop="url"><a href="https://www.hhs.gov/open" class="no-link">HHS/Open</a></span>
        </span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.usa.gov/" class="no-link">USA.gov</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact2.html -->

					</li>
				</ul>
			</div>
		</div>
	</div>
</footer>			<!-- /#footer -->
			<div id="totop" class="off visible-one">Top</div>
        </div>
		<script>page_timing.libs_start = Date.now();</script><script src="../../TemplatePackage/3.0/js/libs.min.js@3.2.1.7"></script><script>page_timing.libs_end = Date.now();page_timing.core_start = Date.now();</script><script src="../../TemplatePackage/3.0/js/core.min.js@3.2.1.7"></script><script>page_timing.core_end = Date.now();</script><!-- Start Site Settings Overrides -->
<script>
CDC.Constants.set("flexSliderVideoDomains", ['youtube.com','ytimg.com','vimeocdn.com'], 'es');
	CDC.Global.settings.includeCDCInBreadCrumbBar=false;
</script>
<!-- End Site Settings Overrides --><script>page_timing.app_start = Date.now();</script><script src="../../TemplatePackage/3.0/js/app.min.js@3.2.1.7"></script><script>page_timing.app_end = Date.now();</script>		
		        			<!-- Begin Survey scripts -->
<script src="../../JScript/foresee/foresee-trigger.js"></script>
<script src="../../JScript/foresee-variables.js"></script>
<!-- End Survey scripts -->
			
            <script>if (typeof page_timing !== 'undefined') { page_timing.metrics_start = Date.now(); }</script>
<!-- xxxxxxxxxxxxxxxxxx METRICS code begins here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<div id="metrics">

<!-- Begin Google DAP inclusion -->
<script type="text/javascript" id="_fed_an_ua_tag" src="../../JScript/metrics/google/Universal-Federated-Analytics-Min.js@agency=HHS&amp;subagency=CDC"></script>
<!-- End Google DAP inclusion -->

<!-- Begin Template Package Custom Interactions -->
<script type="text/javascript" src="../../JScript/metrics/rd_custom_interactions.js"></script>
<!-- End Template Package Custom Interactions -->

<!-- SiteCatalyst code version: H.21. -->
<script src="../../JScript/metrics/topic_levels.js"></script>
<script src="../../JScript/metrics/s_code_v21_cdcgov.js"></script>
<script>

	enquire.register(CDC.Global.selectors.vp1, function() {
		s.prop49 = 1;
	});
	enquire.register(CDC.Global.selectors.vp2, function() {
		s.prop49 = 2;
	});
	enquire.register(CDC.Global.selectors.vp3, function() {
		s.prop49 = 3;
	});
	enquire.register(CDC.Global.selectors.vp4, function() {
		s.prop49 = 4;
	});

            
            


    s.pageName=document.title
    s.channel="STD"
    siteCatalyst.setLevel1("NCHHSTP"); 
    siteCatalyst.setLevel2("DSTDP"); 
    siteCatalyst.setLevel3("Treatment"); 
        

            
                        
            s.prop2=window.location.href;
s.prop26=document.title;
s.prop30=document.title;
s.prop31=window.location.href;
s.prop46=window.location.href;
s.server=window.location.hostname;

// Update the level variables here.
updateVariables(s);

/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
var s_code=s.t();



if(s_code) {
	document.write(s_code);
}



if (document.location.protocol) {


	var cookieManagment = {
		getUuid : function (strPrefix) {
			strPrefix = strPrefix || "";
			var d = new Date();
			var seconds = Math.round(d.getTime() / 1000);
			return strPrefix + Math.floor((1 + Math.random()) * 0x10000).toString(16).substring(1) + "-" + seconds.toString();
		},
		setCookie : function (cname, cvalue, exdays, domain) {
			domain = domain || ".cdc.gov";
			var d = new Date();
			d.setTime(d.getTime() + (exdays*24*60*60*1000));
			var expires = "expires="+ d.toUTCString();
			document.cookie = cname + "=" + cvalue + ";" + expires + ";domain=" + domain + ";path=/";
		},
		getCookie : function (cname) {
			var name = cname + "=";
			var ca = document.cookie.split(';');
			var i = ca.length;
			while (i --) {
				var c = ca[i];
				while (c.charAt(0)==' ') {
					c = c.substring(1);
				}
				if (c.indexOf(name) == 0) {
					return c.substring(name.length,c.length);
				}
			}
			return "";
		},
		init : function () {



			var currCookieVal = cookieManagment.getCookie('cdc_s_vi');

			if (!currCookieVal.length || currCookieVal.indexOf('[CS]v1') != -1) {
				var newCookieVal = cookieManagment.getUuid('[CS]v2') + "-" + cookieManagment.getUuid('');
				cookieManagment.setCookie("cdc_s_vi", newCookieVal, 7);
				return newCookieVal;
			}
			return currCookieVal;
		}
	};


	var cdcSessionID = cookieManagment.init();

	s3 = s_gi("cdcgovvistorid");

	var sKey, override = {
		fun: "cdcgovvistorid",
		trackingServer: "cdc.112.2o7.net"
	};

	s3.visitorID = cdcSessionID;

	for (sKey in s) {
		if (s.hasOwnProperty(sKey)) {
			if (override.hasOwnProperty(sKey)) {
				s3[sKey] = override[sKey];

			} else {

			}
		}
	}
	updateVariables(s3);


	var s_code_uvid = s3.t();
	if(s_code_uvid) {
		document.write(s_code_uvid);
	}
}




</script>
<script type="text/javascript">
if(navigator.appVersion.indexOf('MSIE')>=0) { document.write(unescape('%3C')+'\!-'+'-'); }
</script>
<noscript><a href="http://www.omniture.com"><img src="https://smtrics.cdc.gov/b/ss/cdcgov/1/H.21--NS/01/H.21--NS/0" height="1" width="1" alt="Web Analytics" /></a></noscript><!--/DO NOT REMOVE/-->
<!-- End SiteCatalyst code version: H.21. -->
<!-- Begin Template Package DigitalGov Search Support -->
<script type="text/javascript" src="../../JScript/rd_search.js"></script>
<!-- End Template Package DigitalGov Search Support -->
</div>
<!-- xxxxxxxxxxxxxxxxxx METRICS code ends here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<script>if (typeof page_timing !== 'undefined') { page_timing.metrics_end = Date.now(); }</script>
				

<script>
<!--//
 $(document).ready(function () {
  var cdcLeftNav = new CDC.LeftNav("nav-primary");
  cdcLeftNav.render();
 });
//-->
</script>

    	



						    </body>
	</html>
